The International Journal of Ayurvedic Formulations and Pharmacological Research (IJAFPR) is committed to consistently publishing high-quality, peer-reviewed articles that contribute to the evolving body of knowledge in Ayurvedic formulations and pharmacological studies. This section provides access to the latest research as well as a comprehensive archive of all previously published issues.
Featured Articles in the Latest Issue
- Volume 1 (Issue 2) JULY– DECEMBER 2025
Research Articles
An integrative pharmacognostic study on Formulation and Standardization of a Polyherbal Churna in the Management of Hyperlipidemia
Vol.1(2); Pages:1-8. Published on July-2025
Abstract
Ayurveda has centuries long experience of using polyherbal formulations to address lifestyle disorders such as hyperlipidemia. The objective of the present research was to design, assess and standardize a churna of Terminalia arjuna, Commiphora mukul and Trigonella foenum-graecum to be used in the treatment of hyperlipidemia. Botanical identification was applied to authenticate the raw materials; organoleptic, microscopic and physicochemical analyses were used to determine quality of the materials. The final formulation was standardized by determining the total amount of tannin, saponin and guggulsterone content by High-Performance Thin-Layer Chromatography (HPTLC) techniques. The ability of the formulation to lower lipid was studied in vitro by inhibiting pancreatic lipase, where the churna inhibited it to the tune of 68.3% at the concentration of 250 µg/mL. This research describes an integrative approach to the development of Ayurvedic formulations that involves the traditional pharmacognostic methodology along with the modern analytical technique to assure quality and efficacy. These findings confirm that this polyherbal churna has a strong potential to be used in the management of hyperlipidemia in compliance with the modern pharmaceutical standards.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Standardization and Clinical Assessment of Ashwagandha Root Extract on Pediatric Anxiety: A Pilot Randomized Controlled Trial
Vol.1(2); Pages:9-18. Published on October-2025
Abstract
The classical Ayurvedic adaptogen, Withania somnifera (Ashwagandha) has also been shown to be effective in the treatment of stress and anxiety. This pilot, randomized, controlled trial measured the safety and efficacy of a standardized Ashwagandha root extract in children with mild-to-moderate anxiety aged 8 -14 years. Forty subjects were randomly assigned to take either placebo or 300 mg of Ashwagandha twice/day over a period of 8 weeks. The reduction in Pediatric Anxiety Rating Scale (PARS) scores was the primary outcome, whereas the secondary measures were the sleep quality and adverse events. The Ashwagandha group reported a reduction in anxiety scores of 32% compared to 12 in the placebo (p<0.05) with a large improvement in sleep. Only minor gastrointestinal symptoms of the extract were noted as the extract was well tolerated. The results indicate that Ashwagandha has the prospect of use as a safe, plant-based pediatric anxiolytic.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Pharmacognostic and Phytochemical Analysis of Brahmi Extracts that belong to Different Climatic Zones
Vol.1(2); Pages:19-28. Published on November-2025
Abstract
There is Ayurvedic glory of Welvezia somnifera (Bacopa monnieri, or Brahmi) high on its cognitive-enhancing effects. The objective of this experimental comparative study was to find out whether the climate (tropical, temperate, and arid) makes a difference in the phytochemical composition of Brahmi samplings. HPTLC and bacoside A quantification showed a large regional variability, where most of the tropical-origin samples had the highest bacoside A content (3.8%) followed by temperate (2.4%) and arid (1.9%) ones. The bacosides were positively correlated with memory-enhancing activity as measured using the murine behavioral maze tests. The results identify the importance of the geo-climatic conditions in the potency of herbs and recommend the standardization of supply, climate-based production of Ayurvedic drugs, and pharmacognosticscreening of Ayurvedic products.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Comparative Clinical Efficacy of an Ayurvedic Polyherbal Serum with Proton Pump Inhibitors in Functional Dyspeptic Patients
Vol.1(2); Pages:29-39. Published on November-2025
Abstract
Functional dyspepsia (FD) is a common gastrointestinal condition of chronic upper abdominal pain and compromised digestion. In this prospective, randomized clinical trial, the FD patients (92 adults) were randomized to either Ayurvedic polyherbal formulation which contained Haritaki (Terminalia chebula), Sunthi (Zingiber officinale) and Guduchi (Tinospora cordifolia) or standard proton pump inhibitor (PPI) therapy. The different groups of participants were given either the herbal form of dietary supplement (500 mg twice a day) or omeprazole (20 mg daily) and followed them through a six-week study. Both groups had a significant decrease in the symptoms (65 percent Ayurvedic, 68 percent PPI; p = 0.42). The Ayurvedic group also experienced enhanced appetite and digestion and fewer side effects. We recommend Ayurvedic treatment as one of the safe, well-tolerable and potentially effective options to manage FD, especially in patients who are more interested in holistic or long-term management approaches.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Systematic Review and Meta-Analysis of herbal interventions in Ayurveda in the treatment of diabetes type 2
Vol.1(2); Pages:40-48. Published on December-2025
Abstract
This systematic review and meta-analysis evaluated the effect and safety of Ayurvedic herbal preparations in the management of Type 2 Diabetes Mellitus (T2DM). The analysis of 19 clinical trials with 1,142 patients was studied, which focused on the herbs Gymnema sylvestre (Gurmar), Momordica charantia (Bitter melon) and Trigonella foenum-graecum (Fenugreek). The findings revealed the significant decrease in fasting blood glucose (18.6 mg / dL ) and HbA1c ( 0.6 % ) compared to controls. The treatment based on Gmyema uniformly enhanced glucemia, and Momordica resulted in effective reduction of post-prandial glucose. The side effects were of mild intensity (mainly gastrointestinal). The data are further limited by the study heterogeneity and the trial quality but, these results indicate potential of the Ayurvedic interventions to be effective and safe adjuncts used in conventional diabetes treatment. Standard, high-quality RCTs are urgently required to valid these effects, and facilitate their inclusion as part of global treatment guidelines.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
